Download video

ASCO Daily News 2023 Plenary Update - LBA3: ADAURA

2K views

ASCOcancer

1 year ago

ASCO Daily News 2023 Plenary Update - LBA3: ADAURA

ASCO Daily News 2023 Plenary Update - LBA3: ADAURA

ASCO Daily News 2023 Plenary Update - LBA3: ADAURA
6:33
ASCO Daily News 2023 Plenary Update - LBA3: ADAURA
by ASCOcancer
ASCO Daily News 2023 Plenary Update - LBA1: INDIGO
7:10
ASCO Daily News 2023 Plenary Update - LBA1: INDIGO
by ASCOcancer
ASCO Daily News 2023 Plenary Update - LBA2: PROSPECT
11:42
ASCO Daily News 2023 Plenary Update - LBA2: PROSPECT
by ASCOcancer
ASCO Daily News 2023 Plenary Update - LBA4: SWOG S1826
4:19
ASCO Daily News 2023 Plenary Update - LBA4: SWOG S1826
by ASCOcancer
ASCO Daily News 2022 Plenary Update - LBA2: rEECur
6:05
ASCO Daily News 2022 Plenary Update - LBA2: rEECur
by ASCOcancer
ASCO Daily News 2021 Plenary Update - LBA2: JUPITER-02
6:13
ASCO Daily News 2021 Plenary Update - LBA2: JUPITER-02
by ASCOcancer
Update on EBT 101. From HIV cure research to Hepatitis B cure research.
3:20
Update on EBT 101. From HIV cure research to Hepatitis B cure research.
by ZOOM HOSPITAL
UCSF Bay Area Breast Cancer Forum: \\
1:35:38
UCSF Bay Area Breast Cancer Forum: \\"Updates from ASCO 2024”
by UCSF Cancer
ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne
7:15
ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne
by European Society for Medical Oncology (ESMO)
ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial
6:20
ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial
by European Society for Medical Oncology (ESMO)
ASCO23 - LBA3: OS analysis from the ADAURA trial of adjuvant osimertinib in resected EGFR‐mutate...
11:37
ASCO23 - LBA3: OS analysis from the ADAURA trial of adjuvant osimertinib in resected EGFR‐mutate...
by Oncoletter
ADAURA, KEYNOTE-671, and Other Key Advances in Lung Cancer at ASCO23
31:14
ADAURA, KEYNOTE-671, and Other Key Advances in Lung Cancer at ASCO23
by ASCO Podcasts
The ADAURA Trial: 2023 Updates - Targeted Therapies in Lung Cancer 2023
6:00
The ADAURA Trial: 2023 Updates - Targeted Therapies in Lung Cancer 2023
by GRACE - Global Resource for Advancing Cancer Education
Lung cancer at ASCO 2023: ADAURA and ADCs
0:55
Lung cancer at ASCO 2023: ADAURA and ADCs
by VJOncology
ASCO Lung Cancer Roundtable - Trial Updates in NSCLC - ADAURA Trial and Post Surgery EGFR Mutation
16:41
ASCO Lung Cancer Roundtable - Trial Updates in NSCLC - ADAURA Trial and Post Surgery EGFR Mutation
by GRACE - Global Resource for Advancing Cancer Education
The Oncology Brothers Discuss ADAURA Trial Findings
11:20
The Oncology Brothers Discuss ADAURA Trial Findings
by DocWire
ASCO 2023 - AstraZeneca - Positive Results from ADAURA Phase III Trial
11:58
ASCO 2023 - AstraZeneca - Positive Results from ADAURA Phase III Trial
by HPR
Key Points from the Adaura Trial: Osimertinib - Targeted Therapies in Lung Cancer 2023
5:54
Key Points from the Adaura Trial: Osimertinib - Targeted Therapies in Lung Cancer 2023
by GRACE - Global Resource for Advancing Cancer Education
Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC
1:07
Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC
by OncLive
Adjuvant osimertinib in resected EGFRm NSCLC: the OS data from the ADAURA trial
2:20
Adjuvant osimertinib in resected EGFRm NSCLC: the OS data from the ADAURA trial
by OncoInfoTV
ADAURA Trial: Tagrisso \& Resectable EGFR+ - Leading Developments \& Current Questions in Lung Cancer
5:12
ADAURA Trial: Tagrisso \& Resectable EGFR+ - Leading Developments \& Current Questions in Lung Cancer
by GRACE - Global Resource for Advancing Cancer Education